Removal notice to “Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells” [YEXCR Volume 315, Issue 17, 15 October 2009, Pages 2953–2962](S0014482709003358)(10.1016/j.yexcr.2009.07.030);Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells

Experimental Cell Research

Volumn 315, Issue 17, 2009, Pages 2953-2962

  Zhou, Haibin ^a   Shang, Linshan ^a   Li, Xi ^a   Zhang, Xiyu ^a   Gao, Guimin ^a   Guo, Chenhong ^a   Chen, Bingxi ^a   Liu, Qiji ^a   Gong, Yaoqin ^a   Shao, Changshun ^a,b  

^a Key Laboratory of Experimental Teratology   (China)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

ERK; GSK 3 ; Resveratrol; catenin

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LYMPHOID ENHANCER FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RESVERATROL; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 70349472930     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2021.112609     Document Type: Erratum

References (51)

1. Aubin J.E. Bone stem cells. J. Cell. Biochem., Suppl. 30-31 (1998) 73-82
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., and Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
3. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
4. Huelsken J., and Birchmeier W. New aspects of Wnt signaling pathways in higher vertebrates. Curr. Opin. Genet. Dev. 11 (2001) 547-553
5. Logan C.Y., and Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20 (2004) 781-810
6. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F., Saint-Jeannet J.P., and He X. LDL-receptor-related proteins in Wnt signal transduction. Nature 407 (2000) 530-535
7. Mao J., Wang J., Liu B., Pan W., Farr III G.H., Flynn C., Yuan H., Takada S., Kimelman D., Li L., and Wu D. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7 (2001) 801-809
8. Orford K., Crockett C., Jensen J.P., Weissman A.M., and Byers S.W. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem. 272 (1997) 24735-24738
9. Huang H., and He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr. Opin. Cell Biol. 20 (2008) 119-125
10. Peifer M., and Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287 (2000) 1606-1609
11. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M., Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G., Apte S., Adkins W.N., Allgrove J., Arslan-Kirchner M., Batch J.A., Beighton P., Black G.C., Boles R.G., Boon L.M., Borrone C., Brunner H.G., Carle G.F., Dallapiccola B., De Paepe A., Floege B., Halfhide M.L., Hall B., Hennekam R.C., Hirose T., Jans A., Juppner H., Kim C.A., Keppler-Noreuil K., Kohlschuetter A., LaCombe D., Lambert M., Lemyre E., Letteboer T., Peltonen L., Ramesar R.S., Romanengo M., Somer H., Steichen-Gersdorf E., Steinmann B., Sullivan B., Superti-Furga A., Swoboda W., van den Boogaard M.J., Van Hul W., Vikkula M., Votruba M., Zabel B., Garcia T., Baron R., Olsen B.R., and Warman M.L. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
12. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., and Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346 (2002) 1513-1521
13. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X., Adair R., Chee L., FitzGerald M.G., Tulig C., Caruso A., Tzellas N., Bawa A., Franklin B., McGuire S., Nogues X., Gong G., Allen K.M., Anisowicz A., Morales A.J., Lomedico P.T., Recker S.M., Van Eerdewegh P., Recker R.R., and Johnson M.L. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70 (2002) 11-19
14. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass II D.A., Hartmann C., Li L., Hwang T.H., Brayton C.F., Lang R.A., Karsenty G., and Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell. Biol. 157 (2002) 303-314
15. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., Reddy P.S., Bodine P.V., Robinson J.A., Bhat B., Marzolf J., Moran R.A., and Bex F. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res. 18 (2003) 960-974
16. Krishnan V., Bryant H.U., and Macdougald O.A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116 (2006) 1202-1209
17. Hu H., Hilton M.J., Tu X., Yu K., Ornitz D.M., and Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132 (2005) 49-60
18. Hill T.P., Spater D., Taketo M.M., Birchmeier W., and Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell. 8 (2005) 727-738
19. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
20. Harikumar K.B., and Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7 (2008) 1020-1035
21. Frankel E.N., Waterhouse A.L., and Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 341 (1993) 1103-1104
22. Bertelli A.A., Giovannini L., Giannessi D., Migliori M., Bernini W., Fregoni M., and Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 17 (1995) 1-3
23. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., and Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta 235 (1995) 207-219
24. Fremont L. Biological effects of resveratrol. Life Sci. 66 (2000) 663-673
25. Bertelli A.A., Baccalini R., Battaglia E., Falchi M., and Ferrero M.E. Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie 56 (2001) 613-616
26. Igura K., Ohta T., Kuroda Y., and Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 171 (2001) 11-16
27. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., and Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003) 191-196
28. Backesjo C.M., Li Y., Lindgren U., and Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 21 (2006) 993-1002
29. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., and Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 65 (2005) 9943-9952
30. Dai Z., Li Y., Quarles L.D., Song T., Pan W., Zhou H., and Xiao Z. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14 (2007) 806-814
31. Mizutani K., Ikeda K., Kawai Y., and Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 253 (1998) 859-863
32. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., and Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776
33. Semenov M.V., Tamai K., Brott B.K., Kuhl M., Sokol S., and He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 11 (2001) 951-961
34. van de Wetering M., Cavallo R., Dooijes D., van Beest M., van Es J., Loureiro J., Ypma A., Hursh D., Jones T., Bejsovec A., Peifer M., Mortin M., and Clevers H. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88 (1997) 789-799
35. Cheng S.L., Zhang S.F., Nelson T.L., Warlow P.M., and Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif. Tissue Int. 55 (1994) 356-362
36. Stein G.S., Lian J.B., and Owen T.A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. Faseb J. 4 (1990) 3111-3123
37. Bellows C.G., Aubin J.E., and Heersche J.N. Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. Bone Miner. 14 (1991) 27-40
38. Genge B.R., Sauer G.R., Wu L.N., McLean F.M., and Wuthier R.E. Correlation between loss of alkaline phosphatase activity and accumulation of calcium during matrix vesicle-mediated mineralization. J. Biol. Chem. 263 (1988) 18513-18519
39. Gaur T., Lengner C.J., Hovhannisyan H., Bhat R.A., Bodine P.V., Komm B.S., Javed A., van Wijnen A.J., Stein J.L., Stein G.S., and Lian J.B. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280 (2005) 33132-33140
40. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., Bartholomeusz G., Li Y., Pan Y., Li Z., Bargou R.C., Qin J., Lai C.C., Tsai F.J., Tsai C.H., and Hung M.C. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell. 19 (2005) 159-170
41. Klinge C.M., Blankenship K.A., Risinger K.E., Bhatnagar S., Noisin E.L., Sumanasekera W.K., Zhao L., Brey D.M., and Keynton R.S. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem. 280 (2005) 7460-7468
42. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., and Shaughnessy Jr. J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349 (2003) 2483-2494
43. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., Gaur T., Stein G.S., Lian J.B., and Komm B.S. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 18 (2004) 1222-1237
44. Huang J., Gan Q., Han L., Li J., Zhang H., Sun Y., Zhang Z., and Tong T. SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS. ONE. 3 (2008) e1710
45. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., and Nuttall M.E. Playing with bone and fat. J. Cell. Biochem. 98 (2006) 251-266
46. Zayzafoon M., Gathings W.E., and McDonald J.M. Modeled microgravity inhibits osteogenic differentiation of human mesenchymal stem cells and increases adipogenesis. Endocrinology 145 (2004) 2421-2432
47. Muruganandan S., Roman A.A., and Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol. Life Sci. 66 (2009) 236-253
48. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., and Macdougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282 (2007) 14515-14524
49. Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M., Youn M.Y., Takeyama K., Nakamura T., Mezaki Y., Takezawa S., Yogiashi Y., Kitagawa H., Yamada G., Takada S., Minami Y., Shibuya H., Matsumoto K., and Kato S. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat. Cell. Biol. 9 (2007) 1273-1285
50. Joe A.K., Liu H., Suzui M., Vural M.E., Xiao D., and Weinstein I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer. Res. 8 (2002) 893-903
51. Firestein R., Blander G., Michan S., Oberdoerffer P., Ogino S., Campbell J., Bhimavarapu A., Luikenhuis S., de Cabo R., Fuchs C., Hahn W.C., Guarente L.P., and Sinclair D.A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 3 (2008) e2020